Observational survey on variations of prostate cancer incidence by stage in the nord-pas-de-calais region between 1998 and 2004;Enquête observationnelle sur les variations d'incidence par stade des cancers de la prostate dans la région Nord-Pas-de-Calais entre 1998 et 2004

Progres en Urologie

Volumn 18, Issue 1, 2008, Pages 53-59

  Flamand, V ^a   Zini, L ^a   Salleron, J ^a   Fantoni, J C ^a   Biserte, J ^a   Villers, A ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer prostate epidemiology; PSA; Screening; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BLOOD; CANCER STAGING; FRANCE; HUMAN; INCIDENCE; MALE; OBSERVER VARIATION; PATHOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY;

AGED; FRANCE; HUMANS; INCIDENCE; MALE; NEOPLASM STAGING; OBSERVER VARIATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 48649097154     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2007.12.003     Document Type: Article

References (22)

1. Hill C, Doyon F. The frequency of cancer in France: all ages and under age 15, mortality in 2003 and trends since 1968. Bull Cancer 2007;94:7-13.
2. Bauvin E, Remontet L, Grosclaude P. Incidence and mortality of prostate cancer in France: trends between 1978 and 2000. Prog Urol 2003;13:1334-9.
3. Soulie M, Villers A, Grosclaude P, Menegoz F, Schaffer P, Mace-Lesec'h J, et al. Cancer of the prostate in France: results of the survey CCAFU-FRANCIM. Prog Urol 2001;11:478-85.
4. Villers A, Grosclaude P, Haillot O, Abbou C, Richard F, Boccon-Gibod L. Dépistage du cancer de la prostate (I): évolution des connaissances et des pratiques depuis la conférence de consensus de 1989. Prog Urol 1997:508-15.
5. HAS; Élements d'information des hommes envisageants la réalisation d'un dépistage individuel du cancer de la prostate. 2004.
6. Rebillard X, Villers A, Ruffion A, Beuzeboc P, Soulie M, Richaud P, et al. L'AFU. L.C.D.C.D: recommandations 2002 sur le cancer de prostate. Prog Urol 2002;12(Suppl. 2):31-67.
7. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95: 1276-99.
8. Schroder FH, Denis LJ, Kirkels W, DE Koning HJ, Standaert B. European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies. Cancer 1995;76:129-34.
9. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology and End Results (SEER) Program. Oncologist 2007;12:20-37.
10. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004;171:1393-401.
11. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial. Eur Urol 2007;51:659-64.
12. Kopec JA, Goel V, Bunting PS, Neuman J, Sayre EC, Warde P, et al. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol 2005;174:495-9, discussion 499.
13. Paquette EL, Sun L, Paquette LR, Connelly R, Mcleod DG, Moul JW. Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. Urology 2002;60:756-9.
14. Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, et al. Prostate cancer screening in the Tyrol, Austria: experience and results. Eur J Cancer 2000;36:1322-35.
15. Crawford ED. Epidemiology of prostate cancer. Urology 2003;62:3-12.
16. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 2006;24:396-402.
17. Van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, De Koning HJ, Van Der Kwast TH, et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam. J Urol 2005;174:121-5.
18. Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, et al. Screening for prostate cancer: updated experience from the Tyrol study. Can J Urol 2005;12(Suppl 1):7-13, discussion 92-13.
19. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003;361:1122-8.
20. Bauvin E, Soulie M, Ménégoz F, Macé-Lesec'h J, Buémi A, Velten M, et al. Medical and non-medical determinants of prostate cancer management: a population-based study. Eur J Cancer 2003;39:2364-71.
21. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994;152:1905-9.
22. Villers A, Soulie M, Culine S. Épidémiologie et dépistage du cancer de la prostate. Oncologie 2004;6:245-50.